Elevance Health, Inc. $ELV Shares Acquired by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. increased its position in Elevance Health, Inc. (NYSE:ELV - Free Report) by 94.0% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 332,778 shares of the company's stock after acquiring an additional 161,278 shares during the period. Robeco Institutional Asset Management B.V. owned approximately 0.15% of Elevance Health worth $129,391,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the company. Activest Wealth Management increased its position in shares of Elevance Health by 146.2% in the third quarter. Activest Wealth Management now owns 64 shares of the company's stock valued at $25,000 after buying an additional 38 shares in the last quarter. WealthCollab LLC raised its stake in shares of Elevance Health by 42.2% during the 1st quarter. WealthCollab LLC now owns 91 shares of the company's stock worth $27,000 after buying an additional 27 shares during the last quarter. Kilter Group LLC purchased a new stake in shares of Elevance Health in the 2nd quarter worth about $28,000. Main Street Group LTD purchased a new stake in shares of Elevance Health in the 1st quarter worth about $39,000. Finally, Elevation Wealth Partners LLC boosted its position in shares of Elevance Health by 600.0% in the 2nd quarter. Elevation Wealth Partners LLC now owns 105 shares of the company's stock worth $41,000 after buying an additional 90 shares in the last quarter. 89.24% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the stock. Barclays raised their target price on shares of Elevance Health from $457.00 to $469.00 and gave the company an "overweight" rating in a report on Wednesday, October 7th. TD Cowen upped their price target on shares of Elevance Health from $400.00 to $465.00 and gave the company a "buy" rating in a report on Tuesday, July 14th. Sanford C. Bernstein set a $488.00 price target on shares of Elevance Health in a research report on Thursday, July 16th. Leerink Partners raised their price objective on shares of Elevance Health from $364.00 to $395.00 and gave the stock a "market perform" rating in a research note on Friday, July 17th. Finally, Guggenheim raised their price objective on shares of Elevance Health from $455.00 to $460.00 and gave the stock a "buy" rating in a research note on Monday, October 12th. Fifteen research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company's stock. According to MarketBeat.com, Elevance Health presently has a consensus rating of "Moderate Buy" and a consensus target price of $441.71.

Trending Headlines about Elevance Health

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Quarterly results exceeded expectations: Adjusted earnings were $6.99 per share versus the roughly $4.66–$4.71 consensus estimate, while revenue reached $50.44 billion, above expectations of about $49.22 billion. Earnings also increased from $6.03 per share a year earlier. Elevance Health Reports Third Quarter 2026 Results; Raises Full-Year Guidance
• Positive Sentiment: 2026 outlook was raised: Management lifted its underlying earnings baseline to at least $26.75 per share, citing disciplined expense management and better medical-cost performance. Elevance also expects at least 12% adjusted EPS growth in 2027 from the higher earnings base. Elevance lifts 2026 profit forecast on better medical cost management
• Positive Sentiment: Carelon remained a growth driver: Strength in the services business helped offset pressure elsewhere, supporting management’s confidence in future growth. Elevance named Jeff Park president of Carelon, effective December 1, to lead its next expansion phase. Elevance Health Names Jeff Park President of Carelon
• Neutral Sentiment: Elevance declared a quarterly dividend of $1.72 per share, or $6.88 annualized, representing a yield of approximately 1.6%. The payout supports shareholder returns but is unlikely to be the primary near-term trading catalyst.
• Negative Sentiment: Membership pressure remains a concern: The earnings beat occurred despite declining medical membership, increasing investor focus on enrollment trends and the company’s ability to sustain growth.
• Negative Sentiment: Although cost management improved, Elevance operates on a thin net margin, and continued medical-cost inflation or weaker enrollment could limit the benefit of the raised forecast. The shares have also recently traded near a 52-week high, potentially increasing profit-taking risk.

Elevance Health Price Performance

NYSE:ELV opened at $435.26 on Thursday. Elevance Health, Inc. has a 12-month low of $274.84 and a 12-month high of $450.69. The firm has a market cap of $94.39 billion, a price-to-earnings ratio of 19.34, a price-to-earnings-growth ratio of 2.29 and a beta of 0.70. The company's 50-day moving average is $406.59 and its two-hundred day moving average is $389.52. The company has a current ratio of 1.52, a quick ratio of 1.52 and a debt-to-equity ratio of 0.68.

Elevance Health (NYSE:ELV - Get Free Report) last issued its quarterly earnings results on Wednesday, October 21st. The company reported $6.99 EPS for the quarter, topping analysts' consensus estimates of $4.71 by $2.28. The business had revenue of $50.44 billion during the quarter, compared to the consensus estimate of $49.28 billion. Elevance Health had a net margin of 2.47% and a return on equity of 14.64%. The company's quarterly revenue was up .7% compared to the same quarter last year. During the same period in the previous year, the firm posted $6.03 earnings per share. Research analysts expect that Elevance Health, Inc. will post 27.20 EPS for the current year.

Elevance Health Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, December 18th. Shareholders of record on Friday, December 4th will be paid a $1.72 dividend. This represents a $6.88 annualized dividend and a yield of 1.6%. The ex-dividend date of this dividend is Friday, December 4th. Elevance Health's payout ratio is presently 30.58%.

About Elevance Health

Elevance Health, Inc NYSE: ELV is a diversified health benefits company that provides health insurance and related services in the United States. Its offerings serve employers, individuals and families, as well as members of government-sponsored programs, including Medicare and Medicaid. The company provides medical, pharmacy, behavioral health and other benefits through a range of health plans and specialty products.

Elevance Health operates its health benefits businesses through a portfolio that includes Blue Cross and Blue Shield-affiliated plans and other insurance offerings.

Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.